SAN DIEGO, Oct. 24, 2016 /PRNewswire/ -- Viriom Inc. is pleased to announce the appointment of Janet Hammond, MD, PhD as a member of its Scientific Advisory Board. Dr. Hammond most recently served as Senior VP and Global Head of Infectious Diseases at F. Hoffmann-La Roche managing early clinical development strategy and implementation.
Dr. Hammond brings to the board her extensive knowledge in the areas of virology and infectious diseases, sound clinical expertise as well as ample regulatory experience. Dr. Hammond began her career as a Clinical Program Head of Clinical Discovery in Virology at GlaxoSmithKline (GSK), where she oversaw founding and development of a new department and its medical strategy, IND submissions, and clinical development of small molecules and vaccines. Subsequently she led the Early Clinical research team at Bristol-Myers Squibb responsible for HIV Early Development and Virology Life Cycle management. Dr. Hammond also served as CMO - Medical Affairs at Valeant, where she was responsible for clinical and pharmacovigilance activities around the globe.
"Dr. Hammond's knowledge and experience in the fields of virology and infectious diseases will serve as an invaluable addition to Viriom's efforts in developing innovative HIV treatments and will enrich its Scientific Advisory Board with a unique perspective," said Nikolay Savchuk, PhD, Chairman of Viriom's Scientific Advisory Board. "We believe that Dr. Hammond's clinical expertise as well as experience in drug development and regulatory affairs will help support Viriom's quest to provide more effective solutions for HIV patients."
"Viriom's innovative research aims at bringing to live the next generation of antiviral treatments that will not only be effective but also affordable, and I am delighted to become a part of the company's renown team and contribute to advancing its novel therapies," said Janet Hammond. After receiving her MD and PhD from the University of Cape Town, South Africa, Dr. Hammond has been an exceptionally active contributor to infectious disease therapies, leading the submission of three New Drug Applications (NDA) and Marketing Authorization Applications, more than ten supplemental NDAs, and more than ten Investigational New Drug (IND) applications in the past thirteen years.
Viriom's Scientific Advisory Board members are prominent medical practitioners and scientists with extensive experience in virology and infectious diseases, working together to provide scientific and clinical advice on the development of novel and affordable therapies against life threatening infections including HIV and hepatitis B.
Viriom Inc. is a late-stage biotech company developing, manufacturing and distributing novel and affordable therapies against life threatening infections such as HIV and HBV. Viriom holds exclusive worldwide rights from F. Hoffmann-La Roche for VM1500, which it is presently developing as an oral AIDS treatment (Elpida® elpivirine) for active HIV infections; and as innovative longer-acting formulations of elpivirine for PrEP and PEP in high-risk patient populations. Viriom is also developing a proprietary therapeutic for chronic HBV infections. Viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of HIV and chronic HBV infections in both developing and developed countries. For more information, please visit www.viriom.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viriom-announces-appointment-of-new-scientific-advisory-board-member-300349413.html